Today Dec 01, 2021
Event Image
Back to Events

CAR-T Abstracts from Atlanta

Wednesday Dec 15, 2021
Event Time 12:15 - 12:45 PM ET
Register Now
Event Faculty

Saad Usmani, MD, MBA, FACP

Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
Event Faculty

Thomas Martin, MD

Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program
Associate Director, Myeloma Program, UCSF
Co-Leader, Cancer Immunology & Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Learning Objectives
1.  Define B-cell maturation antigen (BCMA) directed chimeric antigen receptor T (CAR-T) cell therapy and its potential role in treating relapsed and refractory cases of multiple myeloma (RRMM).
2.  Interpret recent data from key clinical trials of BCMA CAR-T cell therapy on patients with RRMM.
3.  Describe future directions for research on BCMA CAR-T cell therapy on patients with RRMM.

Program Description
Join leading hematology and oncology experts in a concise and informative session covering abstracts from the 2021 American Society of Hematology meeting on advances in chimeric antigen receptor T (CAR-T) cell therapy for relapsed and refractory multiple myeloma (RRMM). B-cell maturation antigen (BCMA) has emerged as a novel treatment target for MM, given its highly selective expression in plasma cells. Presenters will discuss the most up-to-date findings from 2 clinical trials of BCMA-directed CAR-T cell therapy and RRMM, including the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) and a phase 1 study of TNB-383B.

Event Sponsors

The content for this program has been independently developed by Clinical Care Solutions.